# Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.

> **NCT07201688** · PHASE3 · RECRUITING · sponsor: **CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.** · enrollment: 890 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** rhTNK-tPA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07201688
- **Lead sponsor:** CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 890 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07201688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07201688, "Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07201688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*